Since November this year, the new crown Omicon strain (B.1.1.529) has "appeared" in more than 77 countries and regions. The WHO said that Omicron is spreading at an unprecedented speed. The mutant strain of the COVID-19 "Omicron" has been discovered in many countries. Many people are worried about whether the existing detection reagents for the mutant strain can be effectively detected? Recently, Anhui Deepblue Medical Technology Co., Ltd. (hereinafter referred to as "Deepblue Medical") announced that existing reagents can effectively detect Omicon mutant strains.

According to relevant evidence, the transmission capacity of "Omicron" is 3-4 times that of the previous "Delta". Some scholars have pointed out that "Omicron" may be more terrifying than all previous mutants. This mutant strain carries more than 50 mutations in total, and is the most mutated COVID-19 so far. Among them, there are as many as 32 S protein mutations, while Delta only has 16 S protein mutations. Therefore, the strain can avoid the immune system more effectively, so it has a higher transmission capacity. This new strain with extremely strong transmission capacity will pose a great challenge to the epidemic prevention work of all countries in the world. Therefore, the rapid and accurate realization of the The detection of the virus is an urgent technical problem that needs to be broken through in various countries.

As early as the beginning of 2020, Deepblue Medical began research on the sudden new crown virus and responded quickly. Its products have successively passed the British Phase 3B test, the special authorization of BfarM in Germany, etc., and have been included in the white list of French new crown reagent exports and obtained CE certification. At the same time, 10,000 SARS-CoV-2 (IgG/IgM) antibody detection reagents were donated to King's College London through the HSBC Business School of Peking University, which was also highly recognized by King's College London. In response to the needs of rapid detection of new coronavirus and home detection, Deepblue's early independent research and development of new coronavirus detection product layout covers antibody, antigen, and neutralizing antibody detection kits, which can complete rapid sample detection in 15 minutes and at the same time have high sensitivity, which can meet the needs of hospitals and institutions. And home self-test needs.

In response to the latest developments of the virus mutant strain Omicron, Deepblue Medical immediately carried out computer simulation verification of all reported N protein mutation sequences and the target sequences we detected. The results confirmed that all N protein mutation sites are not in our target detection area. Therefore, Omicron’s N protein mutation will not affect the performance of Deepblue COVID-19 (SARS-CoV-2) antigen detection reagent, indicating that Deepblue medical new crown There will be no off-target and missed detection of the antigen detection reagent for Omicron, which can effectively ensure the specificity, accuracy and sensitivity of the detection.

In the future, Deepblue Medical will continue to pay attention to and follow up on the latest coronavirus mutations in a timely manner to ensure the sensitivity and specificity of our company's COVID-19 antigen detection reagents for the mutant strains. In the context of the continuous severe global epidemic, timely update and response of R&D technology will be the key to our continuous innovation. Deepblue Medical is willing to work with the frontline warriors to protect health.